



September 10, 2015

Akebia to Present at the 2015 Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18, 2015 at 10:30 a.m. Eastern Time. The conference will take place at the Grand Hyatt in New York City.

A live audio webcast of the presentations will be available on the company's website at <http://ir.akebia.com/events.cfm>. An archived presentation will be available for 90 days.

About Akebia Therapeutics

[Akebia Therapeutics](#), Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. The company has completed Phase 2 development of its lead product candidate, vadadustat, an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20150910006730/en/): <http://www.businesswire.com/news/home/20150910006730/en/>

Investors:

Akebia Therapeutics, Inc.

Ed Joyce, 617-844-6130

ejoyce@akebia.com

or

Media:

Argot Partners

Eliza Schleifstein, 917-763-8106

Eliza@argotpartners.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media